Verrica Pharmaceuticals Inc., a dermatology therapeutics company, engages in the development and commercialization of medications for the treatment of dermatologic diseases in the United States. The company offers YCANTH (VP-102) a drug-device combination that contains a GMP-controlled formulation of cantharidin for the treatment of molluscum in adult and pediatric patients, as well as for the treatment of common warts. It also develops VP-315, an oncolytic peptide-based injectable therapy that is in phase II clinical trial for the treatment of dermatology oncologic conditions, which include basal cell carcinoma and other dermatological oncology indications. The company has a collaboration and license agreement with Torii Pharmaceutical Co., Ltd. for the development and commercialization of its product candidates for the treatment of molluscum and common warts in Japan; and a license agreement with Lytix Biopharma AS to develop and commercialize VP-315 for use in malignant and pre-malignant dermatological indications. Verrica Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in West Chester, Pennsylvania.
Frequently asked questions
What sector does Verrica Pharmaceuticals Inc (VRCA) operate in?
Verrica Pharmaceuticals Inc belongs to the Healthcare sector and operates in the Biotechnology industry.
What is Verrica Pharmaceuticals Inc (VRCA) current stock price?
As of the latest data, Verrica Pharmaceuticals Inc stock price is $3.42, with a previous close of $3.53. Verrica Pharmaceuticals Inc lost -$0.11 in the last trading session, representing a -3.12% loss.
What is Verrica Pharmaceuticals Inc (VRCA) current market capitalization?
Verrica Pharmaceuticals Inc market cap is approximately 58.75 million.
What is Verrica Pharmaceuticals Inc (VRCA) Earnings Per Share (EPS)?
The trailing EPS is -$1.75, and the forward EPS is -$1.48.
What is Verrica Pharmaceuticals Inc (VRCA) EBITDA?
Verrica Pharmaceuticals Inc EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is -12.78 million.
Does Verrica Pharmaceuticals Inc (VRCA) pay dividends?
No. Verrica Pharmaceuticals Inc does not pay a dividend.
How did Verrica Pharmaceuticals Inc (VRCA) perform in its most recent earnings report?
In the last report (June 30, 2026), Verrica Pharmaceuticals Inc posted an EPS surprise of -14.89% and a revenue surprise of 2.18%.
When is Verrica Pharmaceuticals Inc (VRCA) next earnings report?
Verrica Pharmaceuticals Inc is expected to release its next earnings report on September 30, 2026.
What is Verrica Pharmaceuticals Inc (VRCA) beta (volatility) score?
Verrica Pharmaceuticals Inc has a beta of 1.606, suggesting it is more volatile than the market.
